Talarico. ‘Raising life expectancy offers led to a growth in the U.S. Elderly population, rendering it even more vital that elderly cancer individuals have better usage of clinical cancer remedies and trials,’ Dr. Talarico added. ‘With the development of brand-new, selective, and better tolerated remedies, improved access should be possible.’.. Occasionally the retraction of a paper can be as noteworthy as the publication of 1. Here we list a few of the take-backs of 2010 that left the biomedical community most taken aback.James, A. Solberg, I. Syndikus, J. Kliment, S. Wedel, S. Boehmer, M. Dall’Oglio, L. Coleman, N.J. Vogelzang, C.G. O’Bryan-Tear, K. Staudacher, J. Garcia-Vargas, M.S. Bruland, and O. Sartor for the ALSYMPCA Investigators: Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer.
A.P. Pharma second one fourth net loss decreases to $1.9 million A.P. Pharma, Inc. , a specialty pharmaceutical company, today reported financial results because of its second one fourth ended June 30, 2011 and highlighted its recent corporate improvement.P. Pharma closed an exclusive placement financing for $1.5 million in convertible notes, with an additional $3.0 million open to the business at the traders’ discretion within 2 yrs of the closing date.